|
MX360460B
(es)
|
2008-10-20 |
2018-11-05 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de transtiretina.
|
|
EP2723758B1
(en)
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
|
SI3366775T2
(sl)
|
2011-11-18 |
2025-12-31 |
Alnylam Pharmaceuticals, Inc. |
Modificirana sredstva RNAI
|
|
KR102213609B1
(ko)
|
2012-07-13 |
2021-02-08 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
EA038792B1
(ru)
|
2013-05-22 |
2021-10-20 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
IL316808A
(en)
*
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
US20160319278A1
(en)
|
2015-04-03 |
2016-11-03 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
CN115927335A
(zh)
|
2015-04-13 |
2023-04-07 |
阿尔尼拉姆医药品有限公司 |
类血管生成素3（ANGPTL3）iRNA组合物及其使用方法
|
|
PT3329002T
(pt)
|
2015-07-31 |
2021-01-12 |
Alnylam Pharmaceuticals Inc |
Composições de iarn de transtirretina (ttr) e métodos de seu uso para tratamento ou prevenção de doenças associadas à ttr
|
|
WO2017030973A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
CA3012700A1
(en)
*
|
2016-02-01 |
2017-08-10 |
Arrakis Therapeutics, Inc. |
Compounds and methods of treating rna-mediated diseases
|
|
WO2017173297A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Beta-catenin nucleic acids and uses thereof
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
WO2017173301A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Egfr nucleic acids and uses thereof
|
|
EP3436585B1
(en)
|
2016-04-01 |
2022-07-20 |
Avidity Biosciences, Inc. |
Kras nucleic acids and uses thereof
|
|
MX2018015109A
(es)
|
2016-06-06 |
2019-04-22 |
Arrowhead Pharmaceuticals Inc |
Nucleotidos modificados con 5'-ciclo-fosfonato.
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CA3033867A1
(en)
*
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
EP3535274A4
(en)
*
|
2016-11-07 |
2020-07-29 |
Nanosur LLC |
Post-transcriptionally chemically modified double stranded RNA
|
|
US11447519B2
(en)
|
2016-11-10 |
2022-09-20 |
San Diego State University Research Foundation |
Compounds for fluorescence sensing of duplex formation
|
|
TWI788312B
(zh)
*
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
US11504391B1
(en)
*
|
2016-11-23 |
2022-11-22 |
Alnylam Pharmaceuticals, Inc. |
Modified RNA agents with reduced off-target effect
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
CN110225770B
(zh)
|
2016-12-14 |
2022-04-26 |
杨森生物科技公司 |
结合cd8a的纤连蛋白iii型结构域
|
|
WO2018112320A1
(en)
*
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
DK3607069T3
(da)
*
|
2017-04-05 |
2022-11-21 |
Silence Therapeutics Gmbh |
Produkter og sammensætninger
|
|
SI3607068T1
(sl)
*
|
2017-04-05 |
2023-02-28 |
Silence Therapeutics Gmbh |
Z RNA interferenco posredovano inhibiranje TMPRSS6
|
|
EP3550022A1
(en)
*
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions
|
|
JP7406793B2
(ja)
|
2017-06-23 |
2023-12-28 |
ユニバーシティー オブ マサチューセッツ |
２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
|
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|
|
TN2020000038A1
(en)
|
2017-09-14 |
2021-10-04 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
|
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
|
EP3691657A4
(en)
|
2017-10-04 |
2021-07-21 |
Avidity Biosciences, Inc. |
NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
CN111527206A
(zh)
*
|
2017-11-13 |
2020-08-11 |
赛伦斯治疗有限责任公司 |
用于抑制靶标基因表达的包含二硫代磷酸酯键的核酸
|
|
WO2019109046A1
(en)
|
2017-11-30 |
2019-06-06 |
Arrakis Therapeutics, Inc. |
Nucleic acid-binding photoprobes and uses thereof
|
|
WO2019105404A1
(zh)
*
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
EP3719126B1
(en)
|
2017-12-01 |
2025-01-01 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
EP3719127A4
(en)
|
2017-12-01 |
2021-10-20 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
|
|
CN110945131B
(zh)
*
|
2017-12-01 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110944675B9
(zh)
*
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CA3083970A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
DK3719128T3
(da)
*
|
2017-12-01 |
2025-03-03 |
Suzhou Ribo Life Science Co Ltd |
Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
EP3728281A1
(en)
*
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Chirally-enriched double-stranded rna agents
|
|
WO2019127004A1
(zh)
*
|
2017-12-26 |
2019-07-04 |
广州市锐博生物科技有限公司 |
修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物
|
|
AU2018394875B2
(en)
|
2017-12-29 |
2023-08-03 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
EP3740248A4
(en)
*
|
2018-03-02 |
2022-01-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for treating bile duct paucity-associated conditions
|
|
EP3775209A1
(en)
*
|
2018-04-05 |
2021-02-17 |
Silence Therapeutics GmbH |
Sirnas with at least two ligands at different ends
|
|
KR102857148B1
(ko)
*
|
2018-04-05 |
2025-09-11 |
사일런스 테라퓨틱스 게엠베하 |
안티센스 가닥의 5' 단부에 비닐포스포네이트를 갖는 siRNA
|
|
WO2019217397A2
(en)
*
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for improving strand biased
|
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
JP7384833B2
(ja)
*
|
2018-05-16 |
2023-11-21 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
オフターゲット効果が低下した修飾ｒｎａ剤
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
US11279930B2
(en)
*
|
2018-08-23 |
2022-03-22 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
WO2020069055A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
US11896674B2
(en)
|
2018-09-30 |
2024-02-13 |
Suzhou Ribo Life Science Co., Ltd. |
SiRNA conjugate, preparation method therefor and use thereof
|
|
WO2020097044A1
(en)
*
|
2018-11-09 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Modified double stranded oligonucleotides
|
|
WO2020123410A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
|
AU2019398101B2
(en)
|
2018-12-10 |
2025-12-18 |
Amgen Inc. |
Mutated piggybac transposase
|
|
AU2019405783B2
(en)
*
|
2018-12-19 |
2026-03-26 |
Alnylam Pharmaceuticals, Inc. |
Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
|
|
RS67553B1
(sr)
|
2018-12-20 |
2026-01-30 |
Humabs Biomed Sa |
Kombinovana hbv terapija
|
|
WO2020135673A1
(zh)
*
|
2018-12-28 |
2020-07-02 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111378657B
(zh)
*
|
2018-12-28 |
2024-03-15 |
苏州瑞博生物技术股份有限公司 |
抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN111378658B
(zh)
*
|
2018-12-28 |
2024-03-15 |
苏州瑞博生物技术股份有限公司 |
抑制TIMP-1基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
WO2020135581A1
(zh)
*
|
2018-12-28 |
2020-07-02 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111378655B
(zh)
*
|
2018-12-28 |
2024-03-19 |
苏州瑞博生物技术股份有限公司 |
抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN111378659B
(zh)
*
|
2018-12-29 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
抑制stat3基因表达的核酸、含有该核酸的药物组合物及其用途
|
|
CN113330117B
(zh)
*
|
2019-01-18 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113614232A
(zh)
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
JP2022528487A
(ja)
*
|
2019-03-29 |
2022-06-13 |
ユニバーシティ・オブ・マサチューセッツ |
Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
|
|
US11629347B2
(en)
|
2019-05-06 |
2023-04-18 |
University Of Massachusetts |
Anti-C9ORF72 oligonucleotides and related methods
|
|
PH12021552870A1
(en)
*
|
2019-05-13 |
2022-03-21 |
Vir Biotechnology Inc |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
AU2020279101B2
(en)
*
|
2019-05-17 |
2025-07-24 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
US12590304B2
(en)
|
2019-05-22 |
2026-03-31 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
KR20220011689A
(ko)
*
|
2019-05-22 |
2022-01-28 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
|
|
CN111973619B
(zh)
*
|
2019-05-23 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
US20220315929A1
(en)
*
|
2019-05-24 |
2022-10-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
|
|
CN113795280B
(zh)
*
|
2019-05-24 |
2024-04-05 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CA3141902A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Rnai constructs for inhibiting scap expression and methods of use thereof
|
|
CN112007040B
(zh)
*
|
2019-05-31 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
用于治疗乙型病毒性肝炎的联合用药物
|
|
CN114375296A
(zh)
|
2019-06-06 |
2022-04-19 |
艾维迪提生物科学公司 |
核酸多肽组合物及其用途
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
EP3986475A4
(en)
*
|
2019-06-21 |
2023-07-12 |
Alnylam Pharmaceuticals Inc. |
Structurally defined sirna-dual variable domain immunoglobulin conjugates
|
|
KR20220047989A
(ko)
|
2019-08-09 |
2022-04-19 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
|
|
KR20220062517A
(ko)
|
2019-08-15 |
2022-05-17 |
아이오니스 파마수티컬즈, 인코포레이티드 |
결합 변형된 올리고머 화합물 및 이의 용도
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
CN119119240A
(zh)
|
2019-10-14 |
2024-12-13 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
WO2021092145A1
(en)
*
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
BR112022007795A2
(pt)
*
|
2019-11-06 |
2022-07-05 |
Alnylam Pharmaceuticals Inc |
Administração extra-hepática
|
|
CN112876534B
(zh)
*
|
2019-11-29 |
2024-02-09 |
苏州瑞博生物技术股份有限公司 |
肝靶向化合物及缀合物
|
|
CN115461460A
(zh)
*
|
2020-03-06 |
2022-12-09 |
阿尔尼拉姆医药品有限公司 |
用于抑制转甲状腺素蛋白(ttr)的表达的组合物和方法
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
SI4126066T1
(sl)
|
2020-03-27 |
2026-04-30 |
Avidity Biosciences, Inc. |
Sestavki in postopki zdravljenja mišične distrofije
|
|
AU2021246024A1
(en)
*
|
2020-03-30 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof
|
|
WO2021204216A1
(zh)
*
|
2020-04-08 |
2021-10-14 |
北京瑞博开拓医药科技有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
WO2021242883A1
(en)
|
2020-05-26 |
2021-12-02 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
WO2021257568A1
(en)
*
|
2020-06-16 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
|
CN116209762A
(zh)
*
|
2020-07-30 |
2023-06-02 |
阿达尔克斯制药有限公司 |
Adar依赖性编辑组合物及其使用方法
|
|
US12329828B2
(en)
|
2020-09-16 |
2025-06-17 |
San Diego State University (Sdsu) Foundation |
Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy
|
|
JP7607957B2
(ja)
*
|
2020-09-30 |
2025-01-06 |
納▲タイ▼得（青島）生物医薬有限公司 |
アンギオポエチン様３（ＡＮＧＰＴＬ３）のｓｉＲＮＡ及びその用途
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
CN114685585B
(zh)
*
|
2020-12-31 |
2024-06-04 |
苏州瑞博生物技术股份有限公司 |
核苷酸序列、双链寡核苷酸、药物组合物与缀合物及制备方法和用途
|
|
EP4277636A4
(en)
*
|
2021-01-15 |
2025-11-26 |
Alnylam Pharmaceuticals Inc |
MODIFIED OLIGONUCLEOTIDES
|
|
MX2023008469A
(es)
*
|
2021-01-22 |
2023-11-22 |
Alnylam Pharmaceuticals Inc |
Oligonucleotidos de doble hebra modificados.
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
JP2024508896A
(ja)
|
2021-03-04 |
2024-02-28 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
EP4314296A2
(en)
|
2021-03-29 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
EP4323008A4
(en)
|
2021-04-14 |
2026-02-25 |
Aro Biotherapeutics Company |
FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
|
|
CA3214552A1
(en)
|
2021-04-14 |
2022-10-20 |
Russell C. Addis |
Cd71 binding fibronectin type iii domains
|
|
CN117677699A
(zh)
|
2021-06-23 |
2024-03-08 |
马萨诸塞大学 |
用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物
|
|
AU2022299514A1
(en)
*
|
2021-06-24 |
2024-01-18 |
Sirnaomics, Inc. |
Products and compositions
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
MX2024000981A
(es)
|
2021-07-21 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso.
|
|
CA3227852A1
(en)
*
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
TW202328449A
(zh)
|
2021-09-24 |
2023-07-16 |
美商艾拉倫製藥公司 |
微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法
|
|
CN118369427A
(zh)
|
2021-10-15 |
2024-07-19 |
阿尔尼拉姆医药品有限公司 |
肝外递送irna组合物及其使用方法
|
|
WO2023069495A1
(en)
*
|
2021-10-19 |
2023-04-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
|
|
IL312811A
(en)
|
2021-11-16 |
2024-07-01 |
Shanghai Argo Biopharmaceutical Co Ltd |
Composition and method for inhibiting angiotensinogen (agt) protein expression
|
|
CN118339294A
(zh)
*
|
2021-12-16 |
2024-07-12 |
上海拓界生物医药科技有限公司 |
一种dsRNA、其制备方法及应用
|
|
WO2023131170A1
(zh)
*
|
2022-01-05 |
2023-07-13 |
大睿生物医药科技(上海)有限公司 |
具有核苷酸类似物的双链rna
|
|
US11879125B2
(en)
|
2022-03-16 |
2024-01-23 |
Empirico Inc. |
GalNAc compositions for improving siRNA bioavailability
|
|
EP4495240A1
(en)
|
2022-03-16 |
2025-01-22 |
Daiichi Sankyo Company, Limited |
Sirna for suppressing expression of transferrin receptor-2
|
|
US20250188477A1
(en)
|
2022-03-16 |
2025-06-12 |
Daiichi Sankyo Company, Limited |
CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY
|
|
AU2023245603A1
(en)
|
2022-03-28 |
2024-11-07 |
Empirico Inc. |
Modified oligonucleotides
|
|
WO2024077148A1
(en)
*
|
2022-10-07 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Plasminogen (plg) irna compositions and methods of use thereof
|
|
AU2023408479A1
(en)
|
2022-12-19 |
2025-05-01 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar)
|
|
JP2026503499A
(ja)
|
2023-01-20 |
2026-01-29 |
石薬集団中奇制薬技術（石家庄）有限公司 |
修飾されたヌクレオシド単量体及び二本鎖リボ核酸
|
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
EP4669750A2
(en)
|
2023-02-21 |
2025-12-31 |
Vib Vzw |
SYNAPTOGYRIN-3 EXPRESSION INHIBITORS
|
|
KR20250174651A
(ko)
|
2023-04-06 |
2025-12-12 |
상하이 아르고 바이오파마슈티칼 씨오., 엘티디. |
5'-포스포네이트 변형 뉴클레오시드 유사체 및 이로부터 제조된 올리고뉴클레오티드
|
|
EP4704858A1
(en)
*
|
2023-05-03 |
2026-03-11 |
Ionis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides and uses thereof
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
EP4562158A1
(en)
|
2023-06-13 |
2025-06-04 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar) for angiotensinogen
|
|
WO2024263883A2
(en)
*
|
2023-06-22 |
2024-12-26 |
The University Of North Carolina At Chapel Hill |
5' antisense dna modifications to enhance rna interference activity
|
|
EP4735602A2
(en)
|
2023-06-27 |
2026-05-06 |
Atrium Therapeutics, Inc. |
Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
|
|
AU2024308906A1
(en)
|
2023-06-30 |
2026-02-05 |
Atrium Therapeutics, Inc. |
Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
|
|
CN118063533B
(zh)
*
|
2023-09-18 |
2024-08-27 |
广州必贝特医药股份有限公司 |
修饰的核苷酸化合物、其寡聚核苷酸及其应用
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
CN117534717A
(zh)
*
|
2024-01-09 |
2024-02-09 |
凯莱英生命科学技术(天津)有限公司 |
5′-(e)-乙烯基磷酸酯的合成方法
|
|
EP4671372A3
(en)
|
2024-01-29 |
2026-03-11 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
WO2025165891A1
(en)
|
2024-01-29 |
2025-08-07 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
WO2026041784A1
(en)
|
2024-08-23 |
2026-02-26 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
WO2026054553A1
(ko)
*
|
2024-09-06 |
2026-03-12 |
올릭스 주식회사 |
선천성 면역 반응 기반 항암 요법을 위한 이중 가닥 rna 및 이의 용도
|
|
WO2026052078A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|
|
WO2026052079A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|